TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentado lun, 9 nov · 08:15 GMT-6LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk ReductionTodos los ensayos Late-Breaking Science →

CTX310

2026

CTX310: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia, phase 1b

In adults with severe hypertriglyceridaemia, a single infusion of CTX310, CRISPR-Cas9 editing of ANGPTL3, lowered circulating ANGPTL3 and triglycerides at 30 days without treatment-related serious adverse events.

Resultado

Variable principal: Safety to 12 months; lipid changes

At Day 30, mean reduction in circulating ANGPTL3 protein of 65% and mean triglyceride reduction of 63%. Mean reductions of 51% in non-HDL-C and 23% in apolipoprotein B, and a mean LDL-C reduction of 16% from a low mean baseline of 60 mg/dL. Reductions in ANGPTL3 and triglycerides were maintained in participants followed for at least 90 days. No serious adverse events and no Grade 3 or higher adverse events related to CTX310, no clinically relevant AST or ALT elevations, and no acute pancreatitis on study. One participant had a Grade 2 infusion-related reaction, which resolved.

Publicación original
Subtema
Gene editing
Diseño
Phase 1, open-label, ascending-dose, first-in-human trial (CRISPR Therapeutics; US, UK, Australia, New Zealand) of a single intravenous infusion of CTX310, lipid-nanoparticle CRISPR-Cas9 editing of ANGPTL3, in refractory dyslipidaemias; the phase 1b part in severe hypertriglyceridaemia is presented
Incluidos
10 pacientes
Fuente
Sarraju A. Presented at AHA Scientific Sessions 2026, 9 November. CRISPR Therapeutics press release. Not yet published.

Discusión y crítica

In 10 participants with severe hypertriglyceridaemia, all with diabetes and three with prior pancreatitis, a single infusion produced large early falls in ANGPTL3 and triglycerides without treatment-related serious adverse events. The data are short term: efficacy is reported at Day 30, with durability described only as maintained in participants followed for at least 90 days. The study is open label and single arm with no comparator, and the outcomes are biomarkers, so it cannot show any effect on pancreatitis or cardiovascular events. The figures come from a sponsor press release without confidence intervals, individual-level data or a stated primary endpoint, and the trial is ongoing.